New approaches: what is in progress The review by Jandacek and Woods (3), although an excellent overview of recent antiobesity therapeutic strategies, provides by the authors own admission, a narrow view of current research activity and omits several new areas of obesity research
Your healthcare provider increases the dosage of retatrutide gradually every 4 weeks to minimize the risk of side effects
A well-established part of how they work is slowing gastric emptying, so food stays in the stomach longer, and this is documented in the FDA prescribing information for these drugs
GLP-1 receptor agonists like Ozempic (Semaglutide), Mounjaro (Tirzepatide), and Wegovy have revolutionized medical weight loss
Due to the fact that GLP-1 acting drugs such as dulaglutide, liraglutide, and semaglutide do not need dosage adjustments for patients with renal impairment, these medications are considered to be the most recommended choices for patients who have chronic kidney disease (Zheng et al
